Clinical trials: Primary Insomnia
Primary Insomnia
The Role of Partial Reinforcement in the Long Term Management of Insomnia
The lack of scientific attention devoted to the placebo effect as a phenomenon in its own right probably reflects the paucity of theoretical positions within which to organize the existing data and design new research.
- Trial name
- ADER (NCT00662155)
- Testing
- Zolpidem
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- University of Pennsylvania
Primary Insomnia
Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)
This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time…
- Trial name
- NCT01097629
- Testing
- Suvorexant High Dose (HD), Suvorexant Low Dose (LD)
- Volunteers
- 1,020 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia, Secondary Insomnia
Two Contrasting Interventions for Sleep Management
This study will determine whether Mind-Body Bridging (MBB), a mindfulness training program is more effective than a common sleep medication, Zolpidem, in treating insomnia.
- Trial name
- NCT01804036
- Testing
- Zolpidem, Mind-Body Bridging
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Utah
Insomnia, Primary, Depression
Sleep to Prevent Evolving Affecting Disorders
The primary objective of the proposed research is to determine the efficacy of Digital Cognitive Behavior Therapy (dCBTI) in reducing severity of depression and also in preventing the incidence and relapse of depression among…
- Trial name
- SPREAD (NCT02988375)
- Testing
- dCBTI, Sleep Education
- Where
- United States
- Volunteers
- 1,385 people
- Sponsor
- Henry Ford Health System
Migraine, Headache
RELAXaHEAD for Headache Patients (Phase II)
The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of migraine and sleep.
- Conditions
- Migraine, Headache, Multiple Sclerosis, Insomnia
- Trial name
- NCT05466682
- Testing
- Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- NYU Langone Health
Insomnia, Primary Insomnia
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
The purpose of this study is to learn more about people with insomnia disorder and cognitive impairment. Cognitive impairment is difficulty with mental abilities such as thinking, knowing and remembering.
- Conditions
- Insomnia, Primary Insomnia, Chronic Insomnia
- Trial name
- NCT02290405
- Testing
- Multiple Sleep Latency Test (MSLT)
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Jack Edinger, PhD
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Insomnia, Primary Insomnia
Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing
We want to assess whether "how and when" one takes sleep medication results in similar or different outcomes with respect to symptom relief.
- Conditions
- Insomnia, Primary Insomnia, Psychophysiologic Insomnia
- Trial name
- NCT00156533
- Testing
- Zolpidem, Sugar Pill
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Rochester
Sleep Disorder, Primary Insomnia
Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
SKP-1041 is a new formulation of a marketed sleeping agent called zaleplon. Zaleplon is currently available as Sonata as well as several generic formulations. Sonata and its generics induce sleep soon after ingestion.
- Trial name
- NCT00878553
- Testing
- SKP-1041 (experimental formulation of zaleplon)
- Volunteers
- 67 people
- Sponsor
- Somnus Therapeutics, Inc.
Primary Insomnia
Sleep Loss and Mechanisms of Impaired Glucose Metabolism
The purpose of this study is to test the effects of sleep and eszopiclone, a drug that helps people sleep, on how the body processes glucose (sugar). Eszopiclone is approved by the U.S.
- Trial name
- NCT00555750
- Testing
- eszopiclone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Primary Insomnia
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
This is a randomised, placebo controlled study to evaluate the efficacy of a 3 week treatment period with Circadin® 2 mg in shortening sleep latency in patients with primary insomnia aged 18-80 with melatonin deficiency.
- Trial name
- NCT00397189
- Testing
- Circadin
- Where
- United Kingdom
- Volunteers
- 930 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Insomnia, Sleep Initiation and Maintenance Disorders
Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia.
- Conditions
- Insomnia, Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias
- Trial name
- NCT00561821
- Testing
- Esmirtazapine
- Volunteers
- 538 people
- Sponsor
- Merck Sharp & Dohme LLC
Health Personnel, Stress
Cereset Research In Healthcare Workers During COVID-19
The purpose of this study is to evaluate the use of Cereset Research to improve the symptoms of stress in healthcare workers in an open label, waitlist controlled pilot clinical trial, during the period of COVID-19.
- Conditions
- Health Personnel, Stress, Anxiety, Insomnia
- Trial name
- NCT04682197
- Testing
- Cereset Research
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Insomnia
A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)
The purpose of this trial is to investigate the efficacy, safety and tolerability of esmirtazapine (Org 50081) compared to placebo in patients with chronic primary insomnia.
- Trial name
- NCT00506389
- Testing
- Esmirtazapine
- Volunteers
- 419 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
The Psychoneuroimmunology of Insomnia
Chronic insomnia affects approximately 8-9% of the population. The prevalence of this disorder rises dramatically across the lifespan, especially so in women.
- Trial name
- NCT00680771
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Primary Total Hip Arthroplasty, Primary Total Knee Arthroplasty
Total Joint Arthroplasty and Sleep
To compare non-prescription sleep aids (low-dose diphenhydramine and melatonin) to sleep hygiene education for improving postoperative sleep quality after total joint arthroplasty.
- Trial name
- NCT03968939
- Testing
- Diphenhydramine (Benadryl), Melatonin, Sleep Hygiene Education
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- James A. Keeney
Sleep Disorders
Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
This study will compare the symptoms, experiences, and laboratory sleep characteristics of young adults with and without insomnia.
- Trial name
- NCT00177216
- Testing
- Zolpidem, Escitalopram
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Insomnia
A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
The purpose of this study is to evaluate the long-term safety of eszopiclone (2, 3 mg) in non-elderly patients with insomnia and eszopiclone (1, 2 mg) in elderly patients with insomnia.
- Trial name
- NCT00770692
- Testing
- Eszopiclone 1 mg- Elderly, Eszopiclone 2 mg- Elderly, Eszopiclone 3 mg- Non-elderly
- Where
- 34 sites in Japan
- Volunteers
- 369 people
- Sponsor
- Eisai Co., Ltd.
Primary Insomnia
Metabolomics of Insomnia-Related Hyperarousal
Individuals with insomnia have been shown to have higher overall metabolic rates compared to good sleepers, but it is not known which metabolic processes are involved.
- Trial name
- NCT01957111
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Insomnia
Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)
The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries…
- Trial name
- RUBY (NCT00482612)
- Testing
- Esmirtazapine
- Volunteers
- 526 people
- Sponsor
- Merck Sharp & Dohme LLC